Present condition and problems of interferon therapy for chronic hepatitis C.
نویسندگان
چکیده
منابع مشابه
EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کاملInterferon therapy for chronic hepatitis C.
Interferon alone is currently the treatment of choice for chronic hepatitis C. The optimal treatment regimen continues to be defined and refined by clinical studies. The variability of the response to interferon seems to be influenced by several factors, including liver histology, viral genotype, level of viraemia, number of predominant quasispecies, and perhaps the type of interferon and treat...
متن کاملEvolution of Interferon-Based Therapy for Chronic Hepatitis C
Since 1986, interferon-alfa (IFN-α) monotherapy has been administered for patients with chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN-α was a major breakthrough in the treatment of CHC. Sustained virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1 (HCV-1) patients, and i...
متن کاملSarcoidosis after interferon therapy for chronic active hepatitis C.
Sarcoidosis is characterized by multisystemic granulomatous lesions of unknown etiology. A 62-year-old woman developed sarcoidosis after treatment with alpha-2a interferon (IFN) for 24 weeks (total dose: 522 million units) for chronic hepatitis C. She developed complete atrioventricular block and multiple noncaseating granulomatous lesions in the lung. IFN therapy, which may disturb cellular im...
متن کاملefficacy and safety of combination therapy of interferon-alpha 2b plus ribavirin for chronic hepatitis c
introduction: the aim of this study is to assess the therapeutic efficacy and safety of a particular brand of ifn alpha (pdferon b®) in combination with ribavirin (rlba) on iranian patients with chronic hepatitis c (chc). the addition of riba to the standard treatment with interferon (ifn) alpha led to an improvement in sustained virologic response (svr) from less than 20% with ifn monotherapy ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kanzo
سال: 1996
ISSN: 0451-4203,1881-3593
DOI: 10.2957/kanzo.37.539